Chukwuma Ndibe, MD

Description

Chuma Ndibe, M.D., earned his medical degree from University of Nigeria College of Medicine and completed his residency at Morehouse School of Medicine. He is board certified in Medical Oncology, Hematology and Internal Medicine. Prior to joining Piedmont, he was an oncologist/hematologist at Cancer Care Center of Tuscaloosa. Dr. Ndibe specializes in the diagnosis and treatment of cancer and blood disorders. Dr. Ndibe has a special interest in the treatment of lung, breast, colon, prostate, lymphoma and all other cancers. In his spare time, Dr. Ndibe enjoys spending time with his family, reading books and traveling. Dr. Ndibe is accepting new patients and welcomes most major insurance plans.

Keywords decreased hemoglobin, high risk cancer surveillance, iron replacement, immune therapy, immunoassay for tumor antigen ca 15-3 and ca 27-29, immunoassay for tumor antigen ca 125, iron level, iron binding capacity, cancer risk, ferritin, multi-cancer early detection blood test, squamous cell carcinoma, thalassemia trait, family history of clotting, histiocytoma, aranesp injection, octreotide treatment, nucleated red blood cell count, monoclonal paraproteinemia, metastatic rib cancer, nasal cavity cancer chemotherapy, blood transfusion therapy, bladder cancer genomics, large cell cancer of the lung, brain metastases, spine mets, endometrial cancer genomics, endometrial cancer, relapsed hodgkin lymphoma, histiocytic sarcoma, sweat gland carcinoma, wilms tumor 1 mutations, squamous cell carcinoma of the nose, secondary cancer screening, head and neck tumors, squamous cell carcinoma of the tongue, prostate cancer genomics, malignant granular cell tumor, cervical and endometrial cancers, head and neck cancer genomics, breast cancer biological targeted therapy, endocrine complications of cancer therapy, squamous cell carcinoma of the head and neck, melanoma of the lip, malignant carcinoid tumor of colon, gallbladder cancer genomics, chemoradiation, hereditary kidney cancer, sinus cancer, ductal carcinoma in situ (dcis), melanoma genomics, eye cancer, t cell acute lymphoblastic leukemia, kidney cancer, renal cancer genomics, non germinomatous germ cell tumor, face cancer, mucosal melanoma, melanoma on leg, melanoma on trunk, thyroid cancer genomics, melanoma on foot, melanoma on toe, gallbladder cancer, cancer related fatigue, cancer related sexual concerns, vocal cord cancer, hereditary cancer risk, side effects of cancer treatment, ear canal cancer, waldenstrom macroglobulinemia, bone sarcoma, pancreatic cancer genomics, stomach cancer, hormone based chemotherapy, non steroidal aromatase inhibitors, long term side effects of cancer treatment, lung cancer genomics, personal history of chemotherapy, personal history of radiation therapy, orbit cancer, rectal cancer genomics, erythrocytosis, monocytosis, thoracic cancer, ear cancer, chronic neutrophilic leukemia, melanoma of the rectum, skin cancer genomics, papillary meningioma, early detection of cancer, cancer pain, pulmonary metastases, gynecologic cancer, cervical cancer genomics, cervical cancer, lymphoma genomics, renal cell carcinoma immunotherapy, hereditary retinoblastoma, cancer chemotherapy.